Deliver Your News to the World

Abbott Announces Partnership with Velcera to Bring New Pain Medication for Dogs to Market


Abbott Park, Illinois (NYSE: ABT) — Abbott announced today they have partnered with Velcera, Inc., a specialty pharmaceutical company focused on pet health, to market the first canine pain management product delivered in a transmucosal mist form. Currently in clinical trials, the product combines the proven pain medication meloxicam, a nonsteroidal anti-inflammatory drug (NSAID) with Velcera’s patented Promist™ technology, and has been globally licensed for pain management in dogs.

“Abbott Animal Health is dedicated to bringing high quality and innovative treatments to veterinarians and their clients,” said Lynn Bromstedt, divisional vice president, Abbott Animal Health. “This revolutionary pain management product will be a great addition to Abbott’s existing animal health portfolio and could make medication compliance easier for pet owners.”

Promist™ technology delivers the active ingredient through a fine mist to the inside cheek or oral cavity of the animal, where it is quickly absorbed through the mucous membranes of the mouth. Studies show the product is bioequivalent with oral liquid formulations, and bioavailability can be as much as ten times that of a tablet formulation, depending on the active ingredient. 1

In addition to convenience for pet owners, Promist™ technology has several other advantages such as increased dosing confidence, faster absorption than delivery with a tablet or liquid and less concern with food interactions.

“Being able to partner with a trusted company like Abbott on a product of this nature is a testament to the importance of this technology,” said Dennis Steadman, chief executive officer, Velcera. “This agreement will help bring this new treatment method to market for the benefit of pets and pet owners.”

The product will expand Abbott Animal Health’s core focus areas, which currently include products in the areas of diabetes, anesthesia, wound care and fluid therapy, in addition to a recently announced partnership for one of the first cancer medicines designed specifically for dogs.

Under the terms of the agreement, both parties have committed to consider future product developments and registrations using the Promist™ technology.


This news content was configured by WebWire editorial staff. Linking is permitted.

News Release Distribution and Press Release Distribution Services Provided by WebWire.